A Phase I/II, Multi-Center, Open Label Study of DYP688 in Patients with Metastatic Uveal Melanoma (MUM) and Other GNAQ/11 Mutant Melanomas
2022
Mixed Results With Fecal Transplant to Stimulate Cancer Immunotherapy Response
Fecal microbiome transplant (FMT) produced mixed results for stimulating response to immunotherapy in advanced melanoma, according to two preliminary studies.
Sotigalimab/Pembrolizumab Combo Continues to Show Clinical Activity in Frontline Melanoma
The combination of sotigalimab (APX005M) and pembrolizumab (Keytruda) showed encouraging antitumor activity and was well tolerated in the frontline setting of patients with metastatic melanoma, according to updated phase 1/2 findings presented during the 2022 SITC Annual Meeting.
Tumor Infiltrating Lymphocyte Data Signal Promise for New Options to Treat Advanced Melanoma
In an interview with Targeted Oncology, Ryan J. Sullivan, MD, discussed the history of tumor infiltrating lymphocyte therapy, how new data may lead to approved agents in the future, and other ways tumor infiltrating lymphocytes may be used in advanced melanoma.